The United States has recorded two measles deaths as cases reach their highest level in 35 years. Pennsylvania has reported more than 900 cases and is leading the national outbreak.
11:08 AMAl Jazeera23 stories from 8 sources
Outbreaks strain care as health policy and drug markets shift
Day’s Recap
The period therefore combined immediate threats to basic care with longer-term fights over who controls health policy, evidence, and access.
Supporting Articles
The Ebola outbreak has severely disrupted routine healthcare in the hardest-hit communities in the Democratic Republic of Congo. Fear of infection and pressure on hospitals are reducing childhood immunizations and discouraging patients from seeking maternity and other basic services.
1:06 AMBloomberg Markets
Doctors in Gaza are treating patients amid severe shortages of diagnostic equipment and supplies. The lack of testing is forcing medical staff to make decisions while patients wait for diagnoses.
3:26 AMAl Jazeera
AstraZeneca is investing $2 billion in Summit Therapeutics to test the PD-1/VEGF bispecific antibody ivonescimab alongside AstraZeneca's antibody-drug conjugates. The collaboration will evaluate whether the combination can improve cancer treatment outcomes.
9:52 AMStat News
A health department nominee, Overton, will not receive a Senate vote before the midterm elections, while other nominees remain pending. The election timetable could determine which health policy officials ultimately take office.
12:14 PMStat News
The midterm elections could reshape drug pricing rules, Medicaid policy, and federal research funding. The outcomes would affect hospitals, pharmaceutical companies, patients, and research institutions.
4:30 AMStat NewsFederal prosecutors in Florida charged two Indian nationals with allegedly smuggling counterfeit Ozempic from China. The case comes as demand for GLP-1 drugs for weight loss reaches new highs among U.S. adults.
4:18 PMCNBC11:08 AMAl Jazeera
CDC reports two measles deaths in US as cases hit 35-year high
Summary
The United States has recorded two measles deaths as cases reach their highest level in 35 years. Pennsylvania has reported more than 900 cases and is leading the national outbreak.
The deaths and case surge show that measles transmission is no longer confined to isolated
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A preventable disease is again causing deaths and testing the country's outbreak response.
1:06 AMBloomberg Markets
Ebola Disrupts Congo’s Childhood Vaccinations, Maternity and Health Services
Summary
The Ebola outbreak has severely disrupted routine healthcare in the hardest-hit communities in the Democratic Republic of Congo. Fear of infection and pressure on hospitals are reducing childhood immunizations and discouraging patients from seeking maternity and other basic services.
The outbreak is undermining care beyond Ebola treatment itself, creating gaps in vaccination and maternal
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Ebola containment can generate broader health risks if fear and hospital strain interrupt essential preventive and maternity care.
3:26 AMAl Jazeera
Gaza doctors face tough decisions as patients face long waits for diagnoses
Summary
Doctors in Gaza are treating patients amid severe shortages of diagnostic equipment and supplies. The lack of testing is forcing medical staff to make decisions while patients wait for diagnoses.
The collapse of diagnostic capacity turns treatable uncertainty into delayed or improvised care, increasing the
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The shortage is damaging not only immediate care but also the ability to detect chronic illness, infection, and trauma complications early.
9:52 AMStat News
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
Summary
AstraZeneca is investing $2 billion in Summit Therapeutics to test the PD-1/VEGF bispecific antibody ivonescimab alongside AstraZeneca's antibody-drug conjugates. The collaboration will evaluate whether the combination can improve cancer treatment outcomes.
The deal gives AstraZeneca access to a potentially differentiated immunotherapy while pairing it with a
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The investment signals that major cancer-drug companies are pursuing combination regimens to extend the value of established oncology platforms.
2 stories · 2 sources
12:14 PMStat News
STAT+: Overton won’t get a vote before midterms
Summary
A health department nominee, Overton, will not receive a Senate vote before the midterm elections, while other nominees remain pending. The election timetable could determine which health policy officials ultimately take office.
Delaying the vote leaves key health positions unfilled and shifts the confirmation fight into the
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The midterms may decide the personnel and policy direction of the federal health agencies.
4:30 AMStat News
STAT+: Drug pricing, Medicaid, and research funding: The key policy issues at stake in the midterms
Summary
The midterm elections could reshape drug pricing rules, Medicaid policy, and federal research funding. The outcomes would affect hospitals, pharmaceutical companies, patients, and research institutions.
Control of Congress could determine whether recent drug-pricing measures expand, narrow, or stall, while Medicaid
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The elections could alter both the cost of care and the incentives that drive medical innovation.
4:18 PMCNBC
Two Indian nationals charged with smuggling counterfeit Ozempic from China: DOJ
Summary
Federal prosecutors in Florida charged two Indian nationals with allegedly smuggling counterfeit Ozempic from China. The case comes as demand for GLP-1 drugs for weight loss reaches new highs among U.S. adults.
The charges expose how surging demand for GLP-1 drugs is creating an opening for counterfeit
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Counterfeit versions of high-demand weight-loss drugs can turn a supply problem into a direct patient-safety threat.
Other Developments
A curated list of other prominent stories from this day.
Charles Kelley, co-lead vocalist and founding member of Lady A, said he has been diagnosed with multiple myeloma, a rare blood cancer. He shared the diagnosis in a video message and expressed confidence about facing treatment.
7:12 PMVariety
Federal health officials and healthcare executives attended the MAHA Summit, prompting some supporters to question how the movement has evolved. The gathering underscored the growing involvement of institutional and corporate interests in the movement’s agenda.
6:46 PMStat News
Medicare Advantage coverage is expected to cost less next year. Beneficiaries can review and change plans during open enrollment, which begins October 15.
4:57 PMMarketWatch
Some lawmakers are asking the Trump administration to reconsider a pending rule that could block Americans from obtaining medicines through licensed pharmacies abroad. The measure could affect access to drugs imported from Canada and other countries.
4:41 PMStat News
PhRMA has named Eric Cantor as its new chief executive. He takes over as the pharmaceutical industry faces a difficult policy and business environment.
1:56 PMStat NewsSome wealthy and ultra-wealthy Americans are spending as much as $250,000 a year on treatments and monitoring intended to extend healthy lifespan. Doctors are assessing whether these interventions have enough evidence to justify their cost and risks.
9:09 AMCNBC
Researchers found in mice that preventing certain T cells from entering the brain slowed neurodegeneration. The findings suggest that immune-cell trafficking may contribute to disease progression, though the approach has not yet been shown to work in humans.
8:02 AMStat News
UniQure reported that its gene therapy continued to slow Huntington's disease progression four years after treatment. However, the apparent benefit was smaller than in a comparable analysis released a year earlier.
7:05 AMStat News
Novo Nordisk signed its second licensing agreement since investors reacted poorly to the company's long-term strategy presentation. The deal signals continued efforts to strengthen its pipeline and growth prospects through external partnerships.
5:45 AMMarketWatch
Tina L. Cheng, Stanley McChrystal, and James M. Perrin argue that national security depends on children’s health. They present child health as a foundational issue for the country’s future readiness and resilience.
4:30 AMStat News
MAHA advocates, including Robert F. Kennedy Jr., argued that broader access to health data would help researchers investigate vaccines, chronic diseases, and autism. The effort frames data access as central to testing contested health claims.
4:30 AMStat News
Sociologist Jennifer Reich describes lessons from two decades of conversations with parents who decline childhood vaccinations. Her account examines how families explain and make those decisions.
4:30 AMStat News
Medical devices designated as breakthrough products by the FDA will no longer automatically qualify for additional Medicare payments. The article examines devices that received the earlier special treatment.
4:30 AMStat News
Motilal Oswal initiated coverage of Aster DM Quality Care with a Buy rating and a Rs 910 price target. The brokerage expects merger synergies, capacity expansion, and operating improvements to drive revenue, EBITDA, and profit growth through fiscal 2028.
3:10 AMEconomic Times
Harold Hamm has donated $150 million to the University of Oklahoma for diabetes research, the largest gift in the university’s history. The donation comes as Oklahoma ranks near the bottom nationally on health system performance.
3:02 AMFortune7:12 PMVariety
Lady A’s Charles Kelley Shares Blood Cancer Diagnosis: ‘I’m Confident That We’re Going to Get Through It’
Summary
Charles Kelley, co-lead vocalist and founding member of Lady A, said he has been diagnosed with multiple myeloma, a rare blood cancer. He shared the diagnosis in a video message and expressed confidence about facing treatment.
Kelley’s announcement turns a private health issue into a public account of living with a
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A prominent diagnosis brings attention to a rare cancer and to the long-term treatment decisions patients often face.
6:46 PMStat News
STAT+: At MAHA Summit, a grassroots movement goes corporate
Summary
Federal health officials and healthcare executives attended the MAHA Summit, prompting some supporters to question how the movement has evolved. The gathering underscored the growing involvement of institutional and corporate interests in the movement’s agenda.
The summit’s corporate and government presence marks a shift from grassroots organizing toward institutional influence.
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
MAHA’s transition into policy and business circles could determine whether it gains durable influence or loses credibility with its base.
4:57 PMMarketWatch
Medicare Advantage plans will be cheaper next year. Here’s the new cost.
Summary
Medicare Advantage coverage is expected to cost less next year. Beneficiaries can review and change plans during open enrollment, which begins October 15.
Lower premiums could make switching plans more attractive, but beneficiaries still need to compare deductibles,
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A lower headline premium does not guarantee lower overall healthcare costs.
4:41 PMStat News
STAT+: Lawmakers urge Trump to rethink new rule that could restrict imported meds from Canada and overseas
Summary
Some lawmakers are asking the Trump administration to reconsider a pending rule that could block Americans from obtaining medicines through licensed pharmacies abroad. The measure could affect access to drugs imported from Canada and other countries.
The pending rule could narrow a channel that some Americans use to obtain lower-cost medicines,
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Restricting licensed overseas pharmacies could raise medication costs and reduce options for patients already facing high prices.
1:56 PMStat News
STAT+: PhRMA taps Eric Cantor as new CEO
Summary
PhRMA has named Eric Cantor as its new chief executive. He takes over as the pharmaceutical industry faces a difficult policy and business environment.
Cantor will need to strengthen the industry's political position as drugmakers confront pressure over prices,
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
PhRMA's leadership change could shape how aggressively drugmakers fight upcoming policy and pricing battles.
9:09 AMCNBC
Some wealthy Americans are spending up to $250,000 a year on longevity care. Here's what doctors say about the practice
Summary
Some wealthy and ultra-wealthy Americans are spending as much as $250,000 a year on treatments and monitoring intended to extend healthy lifespan. Doctors are assessing whether these interventions have enough evidence to justify their cost and risks.
The longevity market is moving from supplements and wellness programs toward expensive, medically supervised regimens,
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Longevity care is expanding faster than the clinical evidence needed to distinguish useful prevention from expensive medicalization.
8:02 AMStat News
Researchers slow neurodegeneration in mice by barring T cells from the brain
Summary
Researchers found in mice that preventing certain T cells from entering the brain slowed neurodegeneration. The findings suggest that immune-cell trafficking may contribute to disease progression, though the approach has not yet been shown to work in humans.
The decisive finding is that restricting immune access to the brain altered the course of
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The study strengthens the case for targeting immune activity in neurodegeneration while underscoring how far animal evidence remains from a therapy.
7:05 AMStat News
STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years
Summary
UniQure reported that its gene therapy continued to slow Huntington's disease progression four years after treatment. However, the apparent benefit was smaller than in a comparable analysis released a year earlier.
The durability signal remains encouraging, but the reduced effect size weakens the case that the
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The therapy's long-term value now depends on whether its early benefit remains clinically meaningful as follow-up extends.
5:45 AMMarketWatch
Novo Nordisk strikes second licensing deal since frosty capital-markets day
Summary
Novo Nordisk signed its second licensing agreement since investors reacted poorly to the company's long-term strategy presentation. The deal signals continued efforts to strengthen its pipeline and growth prospects through external partnerships.
The licensing activity suggests management is responding to investor pressure with faster business development, rather
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Novo's dealmaking is becoming a test of whether it can rebuild confidence after a weak market reception.
4:30 AMStat News
Opinion: Child health is the national security crisis we keep ignoring
Summary
Tina L. Cheng, Stanley McChrystal, and James M. Perrin argue that national security depends on children’s health. They present child health as a foundational issue for the country’s future readiness and resilience.
Poor child health can reduce educational attainment, workforce capacity, and military eligibility over time, making
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The national security framing could broaden political support for child health spending, but it also puts pressure on policymakers to show measurable long-term returns.
4:30 AMStat News
Why MAHA wants to make health data much more accessible
Summary
MAHA advocates, including Robert F. Kennedy Jr., argued that broader access to health data would help researchers investigate vaccines, chronic diseases, and autism. The effort frames data access as central to testing contested health claims.
The push would lower barriers to research but also intensify disputes over privacy, data quality,
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
More open data could improve independent scrutiny, but weak safeguards could amplify misleading conclusions and erode trust.
4:30 AMStat News
She’s spent two decades talking to parents who don’t vaccinate their children. Here’s what she’s learned
Summary
Sociologist Jennifer Reich describes lessons from two decades of conversations with parents who decline childhood vaccinations. Her account examines how families explain and make those decisions.
Vaccine resistance often reflects distrust, identity, and experiences with institutions rather than a simple lack
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Understanding the social logic of refusal is essential to rebuilding vaccination rates and preventing avoidable outbreaks.
4:30 AMStat News
STAT+: The last ‘breakthrough’ devices to get special treatment from Medicare
Summary
Medical devices designated as breakthrough products by the FDA will no longer automatically qualify for additional Medicare payments. The article examines devices that received the earlier special treatment.
The policy change removes a fast track from FDA recognition to higher Medicare reimbursement. Device
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The shift could slow adoption of novel devices while reducing the risk that Medicare pays a premium without proof of clinical value.
3:10 AMEconomic Times
Motilal Oswal sees Aster DM EBITDA rising 25% CAGR through FY28; sets Rs 910 target
Summary
Motilal Oswal initiated coverage of Aster DM Quality Care with a Buy rating and a Rs 910 price target. The brokerage expects merger synergies, capacity expansion, and operating improvements to drive revenue, EBITDA, and profit growth through fiscal 2028.
The forecast depends on Aster converting its merger benefits and new capacity into sustained utilization
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The call signals strong investor expectations for consolidation and capacity growth in Indian healthcare, but the valuation case relies on aggressive operating delivery.
3:02 AMFortune
Billionaire oil tycoon Harold Hamm donates $150M to the University of Oklahoma to help study a cause that’s personal to him: diabetes
Summary
Harold Hamm has donated $150 million to the University of Oklahoma for diabetes research, the largest gift in the university’s history. The donation comes as Oklahoma ranks near the bottom nationally on health system performance.
The gift gives Oklahoma a major opportunity to build diabetes research and treatment capacity, but
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The donation could strengthen a state health system with deep diabetes needs, while setting a test for whether philanthropy can produce broad public benefits.
Make it yours
Build Your First Pass.
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!